Suppr超能文献

酒精性肝炎与其他肝病在肝移植候补者名单上的结局比较:UNOS 登记处分析。

Liver transplant waitlist outcomes in alcoholic hepatitis compared with other liver diseases: An analysis of UNOS registry.

机构信息

Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI, USA.

Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI, USA.

出版信息

Clin Transplant. 2020 May;34(5):e13837. doi: 10.1111/ctr.13837. Epub 2020 Mar 11.

Abstract

There is growing interest in performing liver transplantation (LT) in patients with alcoholic hepatitis (AH) without a mandated abstinence period. The aim of this study is to investigate waitlist outcomes in AH patients compared to those with other liver diseases. Using data from the UNOS registry, adult patients listed for LT between 2009 and 2018 were evaluated. Waitlist outcomes were compared among liver diseases. A total of 64 646 patients were eligible, including 286 with AH, 16 871 with alcoholic cirrhosis (AC), 13 730 with hepatitis C (HCV), 10 315 with non-alcoholic steatohepatitis (NASH), and 5841 with cholestatic liver disease (CLD). In comparison with AH patients, patients with HCV, NASH, and CLD had a significantly higher risk of waitlist mortality and a lower likelihood of recovery on the waitlist. These trends were more prominent in the waiting-time period of 91-365 days than in shorter periods. In intention-to-treat analysis, positive prognostic effect of LT was significant in AH patients with MELD score ≥35 (HR 0.04, P < .001). AH patients showed lower mortality risk and a higher chance of recovery while on waitlist than other liver diseases, especially when waiting time exceeded 90 days. These results indicate the importance of continuous evaluation of disease progression in AH patients awaiting LT.

摘要

越来越多的人对在没有强制性戒酒期的情况下为酒精性肝炎 (AH) 患者进行肝移植 (LT) 感兴趣。本研究旨在研究 AH 患者与其他肝病患者在等待名单上的结局。使用 UNOS 登记处的数据,评估了 2009 年至 2018 年期间接受 LT 名单的成年患者。比较了不同肝病患者的等待名单结局。共有 64646 名患者符合条件,包括 286 名 AH 患者、16871 名酒精性肝硬化 (AC) 患者、13730 名丙型肝炎 (HCV) 患者、10315 名非酒精性脂肪性肝炎 (NASH) 患者和 5841 名胆汁淤积性肝病 (CLD) 患者。与 AH 患者相比,HCV、NASH 和 CLD 患者在等待名单上的死亡率风险显著更高,而恢复的可能性更低。这些趋势在 91-365 天的等待时间内比在较短的时间内更为明显。意向治疗分析显示,MELD 评分≥35 的 AH 患者 LT 具有显著的预后效果(HR 0.04,P<.001)。AH 患者在等待名单上的死亡率风险较低,恢复的机会较高,而其他肝病患者则相反,尤其是当等待时间超过 90 天。这些结果表明,在等待 LT 的 AH 患者中,持续评估疾病进展非常重要。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验